comparing different acupoints or different forms of acupuncture will be excluded.
113

Types of outcome measures
114
The primary outcome measurement will be improvement in cognitive function. This 
117
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133
The equivalent search words will be used in the Chinese databases.
134
Searching other resources
135
Ambiguous literature will be investigated manually to avoid missing eligible trials.
136
Reference lists of identified publications will also be manually searched. In addition,
137
the following journals published in Chinese will be searched as a supplement: Review Manager software.
160
Assessment of risk of bias
161
The risk and bias in included studies will be assessed by two independent reviewers 162 (LY and SG) using the Cochrane Collaboration's tool. 19 The following domains will 163 be evaluated: selection bias, performance bias, detection bias, attrition bias, reporting 164 bias, and other sources of bias. The assessments will then be classified into three 165 levels: low risk, high risk, and unclear. Unclear items in studies will be inquired by 166 contacting corresponding authors for details. Any disagreement will be resolved by 167 discussion with a third reviewer (WX).
168
Measures of treatment effect
169
For dichotomous data, risk ratio (RR) with 95% CIs will be used for analysis. For 170 continuous data, mean difference (MD) with 95% CIs will be used for analysis.
171
Standardised mean difference (SMD) with 95% CIs will be used if different scales
172
were used to measure a certain outcome variable.
173
Unit of analysis issues
174
The unit of analysis will be the individual participant.
175
Dealing with missing data
176
The corresponding authors will be contacted by reviewers (YY and LY) to obtain 177 missing data. If the missing data are unobtainable, the studies with missing data will 
200
Sensitivity analysis
201
A sensitivity analysis will be conducted to verify the robustness of the review 202 conclusions, if possible. The impacts of methodological quality, sample size, and 203 missing data will be evaluated. Additionally, the analysis will be repeated after low 204 methodological quality studies are excluded.
205
Summary of evidence
206
Results of the outcomes will be summarized in "Summary of findings" tables. The 207 quality of evidence for all outcomes will be assessed through the Grading of The assessments will be adjudicated into four levels: high, moderate, low and very 210 low quality.
211
Ethics and dissemination
212
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134
The following terms will be searched: VD, VaD, vascular dementia, acupuncture,
135
body acupuncture, scalp acupuncture, auricular acupuncture, fire needling, warm 136 needling, and electroacupuncture. The search strategy for PubMed is shown in table 1.
137
The equivalent search words will be used in the Chinese databases. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Ambiguous literature will be investigated manually to avoid missing eligible trials.
143
Reference lists of identified publications will also be manually searched. In addition, exclusion. The study selection procedure is shown in figure 1 .
156
Data extraction and management
157
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Assessment of risk of bias
168
The risk and bias in included studies will be assessed by two independent reviewers 169 (LY and SG) using the Cochrane Collaboration's tool. 19 The following domains will 170 be evaluated: selection bias, performance bias, detection bias, attrition bias, reporting 171 bias, and other sources of bias. The assessments will then be classified into three 172 levels: low risk, high risk, and unclear. Unclear items in studies will be inquired by 173 contacting corresponding authors for details. Any disagreement will be resolved by 174 discussion with a third reviewer (WX).
175
Measures of treatment effect
176
For dichotomous data, risk ratio (RR) with 95% CIs will be used for analysis. For 177 continuous data, mean difference (MD) with 95% CIs will be used for analysis.
178
179
180
Unit of analysis issues
181
182
183
The corresponding authors will be contacted by reviewers (YY and LY) to obtain 
Sensitivity analysis
209
A sensitivity analysis will be conducted to verify the robustness of the review 210 conclusions, if possible. The impacts of methodological quality, sample size, and 211 missing data will be evaluated. Additionally, the analysis will be repeated after low 212 methodological quality studies are excluded.
213
Summary of evidence
214
Results of the outcomes will be summarized in "Summary of findings" tables. The 215 quality of evidence for all outcomes will be assessed through the Grading of
216
Recommendations Assessment Development and Evaluation (GRADE) approach.
19
217
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METHODS
Eligibility criteria 8
Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review P4 Information sources 9 Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage P5 Search strategy 10 Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated P5 Study records:
Page 13 of 14
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